Therewith, we reveal the functional role of a farnesylation substrate PTP4A1, a new synergistic drug combination of an FTI and a ferroptosis-inducing drug, and new cancer subgroups that may benefit from FTI treatment. Here, PTP4A1 is linked to cancer.